Annexin Pharmaceuticals AB (publ) is a Sweden-based biotechnology company. Its main product is ANXV, a human recombinant protein Annexin A5, for emergency treatment of patients with cardiovascular disease with blood vessel damages and inflammation. ANXV has the ability to protect and repair the blood vessels, as well as counteract the inflammation. In addition, the Company has a comprehensive patent portfolio for the treatment of diseases that occur because of damage and blood vessel inflammation. The production process is patented. The Company maintains a cell line for manufacture of Annexin A5. The Companyâ€™s main shareholders are Mikael Loenn, Frostskog AB, Medirista AB and Colinex Capital AB.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-22	12.10 kr	-0.41%	74
26-06-18	12.15 kr	+1.25%	1,220
26-06-17	12.00 kr	-1.64%	12,598
26-06-16	12.20 kr	0.00%	6,797

Delayed Quote Nasdaq Stockholm

More quotes

Income Statement and Estimates

More financial data

Net sales - Rate of surprise

Company calendar

Market Closed - Nasdaq Stockholm Other stock markets 12:00:00 2026-06-22 EDT			5-day change	1st Jan Change
12.10 ^SEK	-0.41%		-0.82%	-38.89%

06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW

Market Cap	85.42M 8.89M 7.77M 7.19M 6.71M 12.59M 840M 12.69M 33.23M 413M 33.39M 32.67M 1.44B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	85.42M 8.89M 7.77M 7.19M 6.71M 12.59M 840M 12.69M 33.23M 413M 33.39M 32.67M 1.44B	EV / Sales 2026 *	1.13x	EV / Sales 2027 *	-
Free-Float	23.86%	Yield 2026 *	-	Yield 2027 *	-

06-15	Five stocks hit new 52-week lows on the Stockholm Stock Exchange today	FW
06-10	Calendar Wednesday June 10	FW
06-09	Calendar Wednesday June 10	FW
05-21	Annexin Pharmaceuticals AB Investigates Three-Day Anxv Treatment Regimen in Patients with Rvo	CI
05-11	Annexin receives German approval for ANXV clinical trial	RE
05-11	Annexin Pharmaceuticals AB Receives Clinical Trial Approval for ANXV in Germany, Widening Patient Recruitment in the Nexus Study	CI
04-23	Annexin Pharmaceuticals AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-22	Annexin Pharmaceuticals AB Provides Update on ANXV Clinical Study in Retinal Vein Occlusion and Diabetic Retinopathy	CI
04-13	Annexin Pharmaceuticals Mulls SEK20 Million Rights Issue; Bridge Facility Secured	MT
04-13	Annexin secures financing through bridge loan facility, plans rights issue	RE
03-26	Seven stocks hit new 52-week lows on the Stockholm Stock Exchange so far today	FW
02-05	Annexin Pharmaceuticals Q4 net loss at SEK 10.5 mln	RE
02-05	Calendar Thursday, February 5	FW

06-15	The subscription period in Annexin Pharmaceuticals’ rights issue begins today	AQ
06-10	Annexin Pharmaceuticals publishes Information document in connection with forthcoming rights issue	AQ
06-05	Annexin Pharmaceuticals to present at Aktiedagarna in Stockholm on June 10	AQ
06-03	Annexin resolves a rights issue of approximately SEK 20 million, secured to approximately 60 percent, with an overallotment option of up to approximately SEK 5 million	AQ
05-21	Annexin investigates a three-day ANXV treatment regimen in patients with RVO	AQ

Annexin Pharmaceuticals AB Stock

Stocks

ANNX

SE0025159387

Biotechnology & Medical Research

Valuation: Annexin Pharmaceuticals AB

Chart: Annexin Pharmaceuticals AB

Latest news : Annexin Pharmaceuticals AB

Press Releases: Annexin Pharmaceuticals AB

News in other languages: Annexin Pharmaceuticals AB

Quotes and Performance

Course Extremes

Managers and Directors: Annexin Pharmaceuticals AB

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates

Net sales - Rate of surprise

1 day	-0.41%
1 week	-0.82%
Current month	-10.70%
1 month	-10.70%
3 months	-13.57%
6 months	-40.10%
Current year	-38.89%

1 week	12	12.2
1 month	11.05	15.05
Current year	11.05	23.6
1 year	11.05	35.8
3 years	11.05	109
5 years	11.05	225
10 years	11.05	1,320

Manager	Title	Age	Since
Nils Anders Haegerstrand CEO	Chief Executive Officer	65	2018-12-31
Anna Frostegård CTO	Chief Tech/Sci/R&D Officer	53	2015-12-31
Susanne Andersson DFI	Director of Finance/CFO	55	2023-04-10

Director	Title	Age	Since
Carl-Fredrik Lindner CHM	Chairman	50	2016-12-31
Curt Mikael von Euler-Chelpin BRD	Director/Board Member	73	-
Jan Nilsson CHM	Chairman	77	2023-12-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ANNEXIN PHARMACEUTICALS AB	-0.41%	-0.82%	-54.17%	-87.40%	8.95M
ARGENX SE	+2.87%	+4.57%	+68.97%	+119.22%	55.19B
WUXI APPTEC CO., LTD.	+4.00%	+7.51%	+63.67%	+68.77%	45.75B
BIONTECH SE	-0.77%	-0.67%	-15.34%	-15.95%	22.98B
INSMED INCORPORATED	+2.93%	+1.17%	-3.97%	+384.78%	20.76B
WUXI BIOLOGICS (CAYMAN) INC.	+1.50%	+3.93%	+27.35%	-17.35%	16.26B
GENMAB A/S	+1.16%	+3.86%	+20.23%	-36.42%	15.42B
EXELIXIS, INC.	-1.08%	-3.11%	+27.20%	+158.30%	13.05B
PHARMAESSENTIA CORPORATION	+3.30%	+15.02%	+133.24%	+273.89%	12.45B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+1.99%	-5.92%	+22.16%	-	12.37B
Average	+1.55%	+1.86%	+28.93%	+94.20%	21.42B
Weighted average by Cap.	+2.23%	+3.17%	+43.54%	+108.88%

	2026 *	2027 *
Net sales	75.6M 7.87M 6.88M 6.36M 5.94M 11.15M 744M 11.23M 29.42M 366M 29.55M 28.91M 1.27B	-
Net income	19.6M 2.04M 1.78M 1.65M 1.54M 2.89M 193M 2.91M 7.63M 94.81M 7.66M 7.5M 329M	-58M -6.04M -5.28M -4.88M -4.56M -8.55M -571M -8.61M -22.57M -281M -22.67M -22.18M -975M
Net Debt	-	-